246 related articles for article (PubMed ID: 16768125)
1. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
[TBL] [Abstract][Full Text] [Related]
2. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
3. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
4. Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model.
Toriniwa Y; Saito T; Miyajima K; Ishii Y; Uno K; Maekawa T; Matsui T; Kume S; Yamada T; Ohta T
J Vet Med Sci; 2018 Jun; 80(6):878-885. PubMed ID: 29643297
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
6. [Drug therapy for non-alcoholic steatohepatitis].
Tomita K; Hibi T
Nihon Rinsho; 2006 Jun; 64(6):1146-51. PubMed ID: 16768123
[TBL] [Abstract][Full Text] [Related]
7. Use of insulin sensitizers in NASH.
Khashab M; Chalasani N
Endocrinol Metab Clin North Am; 2007 Dec; 36(4):1067-87; xi. PubMed ID: 17983937
[TBL] [Abstract][Full Text] [Related]
8. The treatment of NAFLD.
Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
15. [Nonalcoholic steatohepatitis].
Ratziu V; Tahiri M; Bonyhay L
Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S71-80. PubMed ID: 15959406
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Ratziu V; Caldwell S; Neuschwander-Tetri BA
Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
[TBL] [Abstract][Full Text] [Related]
17. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Zhang W; Xu YZ; Liu B; Wu R; Yang YY; Xiao XQ; Zhang X
ScientificWorldJournal; 2014; 2014():603409. PubMed ID: 24558317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
